In S cells, a novel iron-binding intermediate (band D) was identified that was not present in R cells and may be a "sensitivity factor" to gallium.[ncbi.nlm.nih.gov]
In the present study, we investigated the cell-killing effect and mechanism of action of TMZ with flow cytometry using glioblastoma cell lines.[ncbi.nlm.nih.gov]
EMSA analysis from Bryo-1-treated MonoMac6 cells showed an increased nuclear protein binding to the NF-kappaB motif present in the 5' flanking region of the human IFN-gammaR2 promoter that was markedly decreased by pretreatment with the NF-kappaB inhibitor[ncbi.nlm.nih.gov]
In S cells, a novel iron-binding intermediate (band D) was identified that was not present in R cells and may be a “sensitivity factor” to gallium.[jpet.aspetjournals.org]
Presented at the American Society of Hematology 41st Annual Meeting . December 3–7, 1999. New Orleans, LA (abstract 548). Google Scholar 42.[link.springer.com]
This is a clinical case report of a 45-year-old nurse who developed throat irritation and chronic nasalcongestion followed by sinusitis shortly after beginning work at an oncological out-patient clinic.[ncbi.nlm.nih.gov]
This is a clinical case report of a 45-year-old nurse who developed throatirritation and chronic nasal congestion followed by sinusitis shortly after beginning work at an oncological out-patient clinic.[ncbi.nlm.nih.gov]
These included epiphora(17 cases), eye discharge(10 cases), conjunctivitis(6cases ), blurred vision(3 cases), and eye discomfort(2 cases), as well as eye pain, pruritus, dryeye, hordeolum, and visual loss(1 case each).[ncbi.nlm.nih.gov]
These included epiphora(17 cases), eye discharge(10 cases), conjunctivitis(6cases ), blurred vision(3 cases), and eye discomfort(2 cases), as well as eyepain, pruritus, dry eye, hordeolum, and visual loss(1 case each).[ncbi.nlm.nih.gov]
Other adverse effects included myalgias, arthralgias, alopecia, diarrhea, nausea, vomiting, mucositis, and peripheral neuropathy. Rare cases of cardiac and central neurotoxicity were also noted.[ncbi.nlm.nih.gov]
Frequently occurring adverse effects of amsacrine include leukopenia and thrombocytopenia in patients with solid tumors; nausea, vomiting, and diarrhea; mucositis in patients receiving higher doses (leukemia patients); alopecia; hepatotoxicity; and phlebitis[ncbi.nlm.nih.gov]
Other common chemotherapy related side effects such as granulocytopenia or alopecia were not encountered with this agent. Of 24 evaluable pts, two pts had stable disease or minor response and 22 pts had progressive disease.[ncbi.nlm.nih.gov]
Etoposide's dose-limiting toxicity is myelosuppression (leukopenia), which is quite predictable; alopecia and Gl toxicity (nausea, vomiting, stomatitis) occur in about 20-30% of patients given recommended dosages.[ncbi.nlm.nih.gov]
Hair Loss Hair loss, also known as alopecia, is a common side effect of chemotherapy. Hair loss typically begins two to three weeks after chemotherapy begins. Hair usually grows back two to three months after the end of chemotherapy.[livestrong.com]
Serpentine supravenous hyperpigmentation occurs predominately in men who are receiving treatment for solid tumors. Serpentine supravenous hyperpigmentation is an uncommon sequelae of antineoplastic therapy.[ncbi.nlm.nih.gov]
.); For palliative therapy to improve fine wrinkling, mottled hyperpigmentation, roughness associated with photodamage.[drugbank.ca]
Symptoms of central neurotoxicity included somnolence, seizures, dizziness, confusion, and ataxia; symptoms of peripheral neurotoxicity included paresthesias, pain in the extremities, and peripheral neuropathy.[ncbi.nlm.nih.gov]
Symptoms of central neurotoxicity included somnolence, seizures, dizziness, confusion, and ataxia; symptoms of peripheral neurotoxicity included paresthesias, pain in the extremities, and peripheral neuropathy.[ncbi.nlm.nih.gov]
Malignant melanoma cells are particularly well known for their unresponsiveness to chemotherapy; only about 30% of tumors exhibit a transient clinical response to treatment.[ncbi.nlm.nih.gov]
OBJECTIVE: To review the pharmacologic, pharmacokinetic, therapeutic, and safety aspects of irinotecan, a new antineoplastic agent, and to assess its role in the treatment of colorectal and lung cancer.[ncbi.nlm.nih.gov]
For those diagnosed with metastatic breast cancer, the 5-year survival rates are low as, ultimately, patients develop tumors that become refractory to treatment.[ncbi.nlm.nih.gov]
The median total dose and duration of treatment were higher in those developed ophthalmic disorders than in those who did not (12.4 g vs 6.3g and 8.6 months vs 4.4 months).[ncbi.nlm.nih.gov]
It is recommended that neutrophil-count and platelet-count recovery be allowed to occur before the next treatment cycle is begun.[ncbi.nlm.nih.gov]
BACKGROUND: Although patients with neuroendocrine tumors typically exhibit an indolent clinical course, the pace of disease accelerates and the prognosis deteriorates once objective progression of disease begins.[ncbi.nlm.nih.gov]
Hence, the need to take into consideration the prognosis of the disease in assessing the extent of benefit is another sensible distinction to be made.[esmoopen.bmj.com]
As overt HF induced by chemotherapy has such a worse prognosis, there is a stringent need to improve our ability to detect CTRCD at a subclinical level.[romanianjournalcardiology.ro]
Regulatory T cells and CD20 B cells in pediatric very severe aplastic anemia: possible clinical markers for evaluating the therapeutic efficacy and prognosis. Hematology. 2018 Jul 11. 1-5. [Medline]. Brodsky RA. Acquired Aplastic Anemia.[medscape.com]
The Drug Etiology of Agranulocytosis and Aplastic Anemia. New York: Oxford University Press; 1991. Issaragrisil S, Sriratanasatavorn C, Piankijagum A, Vannasaeng S, Porapakkham Y, Leaverton PE, et al. Incidence of aplastic anemia in Bangkok.[medscape.com]
Malignant melanoma in solid transplant recipients: collection of database cases and comparison with surveillance, epidemiology, and end results data for outcome analysis. Arch Dermatol. 2011 Jul. 147(7):790-6. [Medline].[medscape.com]
Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria: a review. Eur J Haematol. 2015 Sep. 95 (3):190-8. [Medline]. Brodsky RA, Mukhina GL, Li S, Nelson KL, Chiurazzi PL, Buckley JT, et al.[medscape.com]
Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention. Rev Port Cardiol. 2013;32(5):395-409 22. Florescu M, Cinteza M, Vinereanu D. Chemotherapy-induced Cardiotoxicity.[romanianjournalcardiology.ro]
Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions a scientific statement from the american heart association.[revistas.uis.edu.co]
[…] that are used to treat various cancers Associated cancers: Cancers of the breast, lung, ovary, liver, and bladder; cancers of the hematopoietic system Most important routes of exposure: Inhalation, skin contact, ingestion, needle stick injury Uses: Prevent[carexcanada.ca]
Inhibiting or preventing the growth or development of malignant cells. an′ti·ne′o·plas′tic n. antineoplastic [-nē′ōplas′tik] Etymology: Gk, anti neos, new, plasma, something formed 1 pertaining to a substance, procedure, or measure that prevents the proliferation[medical-dictionary.thefreedictionary.com]
Moreover, the ability of Bryo-1 to trigger RANTES and MIP1-α suggests that Bryo-1 could potentially be used to prevent HIV-1 infection. Finally, induction of a Th2 response by Bryo-1 may help treat inflammatory diseases mediated by Th1 cells.[ncbi.nlm.nih.gov]
Accurate reporting of emetogenicity of such antineoplastic agents in the absence of preventive antiemetic treatment may not be available.[ncbi.nlm.nih.gov]
Inhibition of RNA or protein synthesis by actinomycin D or cycloheximide did not prevent the antiproliferative action of IFN gamma nor the induction of monocytic differentiation, yet these two compounds blocked the priming effect of IFN gamma on the potentiation[ncbi.nlm.nih.gov]